Afleveringen
-
Michael Mack speaks to Allan Schwartz, a principal investigator of the EARLY TAVR trial, who explains how it informs patient management.
-
Bernard Prendergast and Philippe Généreux detail the EARLY TAVR trial design and outcomes.
-
Zijn er afleveringen die ontbreken?
-
Juan Granada and Pierre Elias discuss how AI is an essential tool for improving screening access and increasing early diagnosis of valvular heart disease.
-
Martha Gulati and Kathyn Berlacher talk about tangible ways to improve women's cardiovascular care, including nontraditional, patient-centered solutions.
-
Clyde Yancy, Suzanne Baron, and Bruce Rutkin discuss ways to address the undertreatment of CVD in women at the patient, provider, structural, and societal levels.
-
Clyde Yancy talks to Priya Freaney and Nisha Parikh about the landscape of cardiovascular care for women and how it can be improved, both for patients and women training to be cardiologists.
-
Sreek Vemulapalli and Roseann White explain the statistical challenges that can arise while collecting longer-term follow-up data during clinical trials.
-
Sreekanth Vemulapalli asks Ryan Ahern about potential data sources that can be used to sustain long-term follow-up in pivotal trials.
-
Ami Bhatt asks Kate Dalton to share details on the challenges of early feasibility studies from her perspective as a clinical site coordinator.
-
Ami Bhatt and Michael Mack explore the ethics of AI use in the detection of subclinical cardiovascular disease.
-
Ami Bhatt and Michael Mack explain the economics of AI use in the detection of subclinical cardiovascular disease.
-
Ami Bhatt and Martin Leon discuss the critical importance of early feasibility studies in the US clinical community.
-
Michael Mack speaks with Stefan Anker about the outcomes and implications of the RESHAPE-HF2 trial.
- Laat meer zien